Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...

Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and ...

Pfizer’s Hympavzi (marstacimab) has been approved in the European Union (EU) to prevent or reduce the frequency of bleeding episodes in adults and children, ages 12 and older, with severe hemophilia A ...

Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union ...

Every company faces challenges. Sometimes, those issues are deeply damaging to a corporation's investment thesis. Other times ...

Data, used for myriad purposes, plays a critical role in life sciences, and cloud-based platforms can ease the organisational ...

Delhi: Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab) ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the ...

Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors: New York Thursday, November 21, 2024, 0 ...

The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...

Teachers from three striking unions have gathered on the steps of the Massachusetts Statehouse to ask lawmakers and ...